Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Mark Burkard, MD, PhD

Advertisement

Articles by Mark Burkard, MD, PhD

What Can We Learn From "Extreme Survivors" of Breast Cancer?

ByMark Burkard, MD, PhD
April 29th 2018

Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.

Advertisement

Latest Updated Articles

  • What Can We Learn From "Extreme Survivors" of Breast Cancer?
    What Can We Learn From "Extreme Survivors" of Breast Cancer?

    April 29th 2018



Advertisement
Advertisement

Trending on OncLive

1

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

2

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

3

Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis

4

CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL

5

Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us